1、Product Data SheetPemetrexed disodiumCat. No.: HY-10820ACAS No.: 150399-23-8分式: CHNNaO分量: 471.37作靶點: Antifolate; Autophagy; Apoptosis作通路: Cell Cycle/DNA Damage; Autophagy; Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 H2O : 100 mg/mL (212.15 mM)* means solu

2、ble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 2.1215 mL 10.6074 mL 21.2148 mL5 mM 0.4243 mL 2.1215 mL 4.2430 mL10 mM 0.2121 mL 1.0607 mL 2.1215 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內使，-20C 儲存時，請

3、在 1 個內使。BIOLOGICAL ACTIVITY物活性 Pemetrexed disodium (LY231514 disodium) 種葉酸拮抗劑 (antifolate)。Pemetrexed disodium (LY231514 disodium) 的五氨酸抑制胸苷酸合成酶 (TS)，氫葉酸還原酶 (DHFR) 和氨酰胺核苷酸甲酰轉移酶 (GARFT)的Ki 分別為 1.3 nM，7.2 nM 和 65 nM。IC & Target Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)1體外研究Pemetrexed (LY231514) dis

4、odium is a novel classical antifolate, the antitumor activity of which may result fromsimultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites.Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (Km=1.6 M and Vm

5、ax/Km=621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles indetermining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderatelyPage 1 of 2 www.MedChemEinhibits TS (Ki=340 nM, recombinant mouse), the

6、pentaglutamate of LY23l5l4 is 100-fold more potent (Ki=3.4 nM),making LY231514 one of the most potent folate-based TS inhibitors1.體內研究 The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. Ina survival analysis, significantly better surviva

7、l is observed in the group of mice treated with PC61 plus Pemetrexedcompare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment2.PROTOCOLKinase Assay 1 AICARFT inhibition assays are carried out at room temperature by monitoring the formation of 6S-5,6,7,8-tetrahydrofolate fr

8、om 10-formyl-6R,S-5,6,7,8-tetrahydrofolate at A298. All solutions are purged with N2 gas prior touse. The reaction solution contains 33 mM Tris-Cl, pH 7.4, 25 mM KCl, 5 mM 2-Mercaptoethanol, 0.05 mM AICAribonucleotide, and 16 nM (2 milliunits/mL) of AICARFT. 10-Formyl-6R,S-5,6,7,8-tetrahydrofolate c

9、oncentrations of0.037, 0.074, and 0.145 mM are used (0.61, 1.23, and 2.45 times its Km value, respectively). LY231514 is tested as aninhibitor at 0.08-0.8 mM (four concentrations). When the tri- and pentaglutamates of LY231514 are used asinhibitors, the concentrations are 0.0005-0.009 mM (eight conc

10、entrations). Enzyme assays are initiated by theaddition of enzyme. Data is analyzed using the ENZFITTER program for competitive inhibition.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 Dose-response curves are generated to determine the c

11、oncentration required for 50% inhibition of growth (IC50).Pemetrexed is dissolved initially in DMSO at a concentration of 4 mg/mL and further diluted with cell culture mediumto the desired concentration. CCRF-CEM leukemia cells in complete medium are added to 24-well Cluster plates at afinal concent

12、ration of 4.8104 cells/well in a total volume of 2 mL. Test compounds at various concentrations areadded to duplicate wells so that the final volume of DMSO is 0.5%. The plates are incubated for 72 h at 37C in anatmosphere of 5% CO2 in air. At the end of the incubation, cell numbers are determined o

13、n a ZBI Coulter counter.Control wells usually contain 4105 to 6105 cells at the end of the incubation. For several studies, IC50s aredetermined for each compound in the presence of either 300 M AICA, 5 M thymidine, 100 M hypoxanthine, orcombination of 5 M hymidine plus 100 M hypoxanthine1.MCE has no

14、t independently confirmed the accuracy of these methods. They are for reference only.Animal Mice2Administration 2 Female CBA mice and female NOD/SCID mice (NOD.CB17-Prkdcscid) at 6-8 wk of age are used. Premetrexed (100mg/kg) is given i.p. from days 4-8 (5 consecutive d) to tumor-bearing mice to exp

15、lore the synergistic effect whencombined with anti-CD25 Ab or IgG control. The dose and schedule used for Pemetrexed in the current study isdetermined based on previous studies in mice.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發(fā)表的科研獻 Mol Cell

16、. 2019 Dec 5;76(5):838-851.e5. Theranostics. 2020 May 15;10(13):6048-6060. J Mol Med (Berl). 2019 Aug;97(8):1183-1193. Acta Pharmacol Sin. 2020 May 12. Beilstein J Org Chem. 2017 Oct 25;13:2252-2263.See more customer validations on HYPERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemEREFERENCES1. Shih C, et al. LY231514, a pyrrolo2,3-dpyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.2. Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J